Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.71 |
| ▸ | EGFR | P00533 | 8/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.70 |
| ▸ | RAF1 | P04049 | 3/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 4/20 | 0.57 |
| ▸ | STK4 | Q13043 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071665 | 0.86 | MAP2K1 (0.77) | MAP2K1EGFRERBB2RAF1GAK | |
| SCHEMBL30301819 | 0.85 | MAP2K1 (0.62) | MAP2K1EGFRERBB2RAF1GAK | |
| SCHEMBL6381476 | 0.85 | EGFR (0.75) | MAP2K1EGFRERBB2RAF1GAK | |
| SCHEMBL17858745 | 0.85 | MAP2K1 (0.62) | MAP2K1EGFRERBB2RAF1GAK | |
| Hydrochloric Acid SCHEMBL17845966 | 0.84 | MAP2K1 (0.61) | MAP2K1EGFRERBB2RAF1GAK | |
| SCHEMBL4097022 | 0.84 | SRC (0.73) | EGFRERBB2GAKSRC | |
| SCHEMBL29207180 | 0.82 | MAPT (0.49) | MAP2K1EGFRERBB2RAF1 | |
| SCHEMBL30849390 | 0.82 | MAPT (0.49) | MAP2K1EGFRERBB2RAF1 | |
| SCHEMBL6382049 | 0.81 | MAP2K1 (0.66) | MAP2K1EGFRERBB2RAF1GAK | |
| SCHEMBL1897881 | 0.80 | EGFR (0.64) | MAP2K1EGFRERBB2RAF1GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888529-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | MAP2K1 818/4885EGFR 4122/4885ERBB2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.